lamivudine has been researched along with Hematologic Malignancies in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (68.00) | 29.6817 |
| 2010's | 8 (32.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, FY; Cheng, Z; Huang, HH; Shi, KQ; Van Poucke, S; Zhang, MY; Zheng, JN; Zheng, MH; Zhu, GQ | 1 |
| Cafro, A; Cairoli, R; Colombo, M; Corradini, P; Dodero, A; Facchetti, F; Grossi, G; Labanca, S; Lampertico, P; Loglio, A; Montefusco, V; Viganò, M | 1 |
| Adinolfi, LE; Boemio, A; Capoluongo, N; Coppola, N; D'Amore, C; Esposito, M; Guastafierro, S; Macera, M; Marrone, A; Mastrullo, L; Minichini, C; Onorato, L; Pisaturo, M; Rinaldi, L; Sagnelli, E; Siniscalchi, I | 1 |
| Angelucci, E; Bruzzone, B; Caligiuri, P; Di Grazia, C; Dominietto, A; Gualandi, F; Lamparelli, T; Mikulska, M; Nicolini, LA; Viscoli, C; Zappulo, E | 1 |
| Andreoni, M; Arcese, W; Battisti, A; Bianchi, A; Cantonetti, M; Cerretti, R; Cerva, C; Colagrossi, L; Cudillo, L; De Angelis, G; Di Carlo, D; Maffongelli, G; Malagnino, V; Perno, CF; Picardi, A; Pollicita, M; Ricciardi, A; Salpini, R; Sarmati, L; Svicher, V | 1 |
| Biemond, BJ; Jansen, PL; Reesink, HW; Takkenberg, RB; ten Cate, DF; Zaaijer, HL | 1 |
| Childs, R; John Barrett, A; Koklanaris, E; Le, Q; Savani, BN; Shenoy, A | 1 |
| Boccadoro, M; Bruno, B; Festuccia, M; Fiore, F; Giaccone, L; Marengo, A; Marzano, A; Pittaluga, F; Resta, I; Rizzetto, M; Sorasio, R | 1 |
| Aki, Z; Haznedar, R; Ozkurt, ZN; Sucak, GT; Yağci, M; Yeğin, ZA | 1 |
| Chang, PY; Chao, TY; Chen, YC; Dai, MS; Ho, CL; Kao, WY; Tsai, SH; Wu, YY; Yu, JC | 1 |
| Rossi, G | 1 |
| Maeda, Y; Okamoto, R; Sasaki, T | 1 |
| Akan, H; Akbulut, H; Arat, M; Arslan, O; Beksaç, M; Bozdayi, M; Idilman, R; Karayalçin, S; Ozcan, M; Ozden, A; Soydan, E; Soykan, I; Törüner, M; Türkyilmaz, AR; Van Thiel, DH | 1 |
| Black, A; Dixon, JS; el-Sayed, MH; el-Tawil, A; Karim, AM; Shanab, G | 1 |
| Borlenghi, E; Cariani, E; Motta, M; Pelizzari, AM; Rossi, G; Turconi, P | 1 |
| Ando, K; Fukuno, K; Hara, T; Imawari, M; Kasahara, S; Moriwaki, H; Onishi, H; Oyama, M; Sawada, M; Takahashi, T; Takai, S; Takami, T; Tomita, E; Tsurumi, H; Yamada, T | 1 |
| Enjoji, M; Kotoh, K; Nakamuta, M; Nawata, H; Noguchi, K; Sugimoto, R; Tsuruta, S | 1 |
| Idilman, R | 2 |
| Au, WY; Cheung, WW; Hui, CK; Kwong, YL; Lau, GK; Leung, N; Liang, R; Lie, AK; Wong, BC; Yueng, YH; Zhang, HY | 1 |
| Garipidou, V; Giouleme, O; Perifanis, V; Tziomalos, K; Vakalopoulou, S; Vassiliadis, T | 1 |
| Chao, TC; Chen, PM; Chiou, TJ; Chu, CJ; Hsiao, LT; Lin, YC; Liu, JH; Tzeng, CH; Wang, WS; Yang, MH; Yen, CC | 1 |
| Acar, K; Aki, Z; Bozdayi, G; Haznedar, R; Sucak, GT; Yağci, M | 1 |
| Motta, M; Pelizzari, A; Puoti, M; Rossi, G | 1 |
| Bourikas, G; Kartalis, G; Kotsiou, S; Margaritis, D; Martinis, G; Mimidis, K; Spanoudakis, E; Tsatalas, C | 1 |
4 review(s) available for lamivudine and Hematologic Malignancies
| Article | Year |
|---|---|
Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis.
Topics: Adenine; Antiviral Agents; Controlled Clinical Trials as Topic; Guanine; Hematologic Neoplasms; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunocompromised Host; Lamivudine; Organophosphonates; Survival Analysis; Telbivudine; Tenofovir; Thymidine; Treatment Outcome; Virus Activation | 2017 |
[Reactivation of hepatitis B virus in patients with hematological neoplasms].
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Antineoplastic Agents; Antiviral Agents; Female; Graft vs Host Disease; Hematologic Neoplasms; Hepatitis B; Hepatitis B virus; Humans; Immunosuppression Therapy; Lamivudine; Male; Risk Factors; Sex Factors; Transplants; Virus Activation | 2009 |
Prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with hemato-oncological neoplasias treated with chemotherapy.
Topics: Antineoplastic Agents; Chronic Disease; Hematologic Neoplasms; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Lamivudine; Virus Activation | 2003 |
[Hepatotoxicity of chemotherapy].
Topics: Antineoplastic Agents; Antiviral Agents; Chemical and Drug Induced Liver Injury; Hematologic Neoplasms; Hepatitis B; Hepatitis C; Humans; Interferon-alpha; Lamivudine; Liver Diseases; Neoplasms; Reverse Transcriptase Inhibitors | 2003 |
8 trial(s) available for lamivudine and Hematologic Malignancies
| Article | Year |
|---|---|
Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
Topics: Adult; Aged; Blood Donors; DNA, Viral; Female; Graft vs Host Disease; Hematologic Neoplasms; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Lamivudine; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Stem Cell Transplantation; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Virus Activation; Young Adult | 2010 |
Hepatitus B virus reactivation in HBV-DNA negative and positive patients with hematological malignancies.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antiviral Agents; DNA, Viral; Female; Hematologic Neoplasms; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Reverse Transcriptase Inhibitors; Risk Factors; Rituximab; Virus Activation | 2010 |
Preventing chemotherapy-induced hepatitis B reactivation in breast cancer patients: a prospective comparison of prophylactic versus deferred preemptive lamivudine.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; DNA, Viral; Drug Administration Schedule; Feasibility Studies; Female; Hematologic Neoplasms; Hepatitis B; Hepatitis B Surface Antigens; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Retrospective Studies; Reverse Transcriptase Inhibitors; Time Factors; Virus Activation | 2011 |
Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Carrier State; DNA, Viral; Female; Hematologic Neoplasms; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Antigens; Hepatitis B virus; Humans; Lamivudine; Male; Middle Aged | 2004 |
Lamivudine facilitates optimal chemotherapy in hepatitis B virus-infected children with hematological malignancies: a preliminary report.
Topics: Adolescent; Antineoplastic Agents; Antiviral Agents; Child; Child, Preschool; Drug Synergism; Female; Hematologic Neoplasms; Hepatitis B; Humans; Immunosuppression Therapy; Lamivudine; Male; Remission Induction; Treatment Outcome; Virus Activation | 2004 |
Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy--a prospective case series.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents; DNA, Viral; Drug Therapy, Combination; Female; Hematologic Neoplasms; Hepatitis B; Hepatitis B virus; Humans; Immunosuppressive Agents; Lamivudine; Male; Middle Aged; Premedication; Prospective Studies; Serologic Tests; Treatment Outcome; Virus Activation | 2005 |
Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients.
Topics: Adult; Antiviral Agents; Drug Resistance; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Male; Middle Aged; Mutation; Premedication; Viral Load; Virus Activation | 2006 |
A prospective study on chemotherapy-induced hepatitis B virus reactivation in chronic HBs Ag carriers with hematologic malignancies and pre-emptive therapy with nucleoside analogues.
Topics: 2-Aminopurine; Adult; Aged; Antineoplastic Agents; Antiviral Agents; Chronic Disease; Famciclovir; Female; Hematologic Neoplasms; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Lamivudine; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nucleosides; Pilot Projects; Prospective Studies; Virus Activation | 2006 |
13 other study(ies) available for lamivudine and Hematologic Malignancies
| Article | Year |
|---|---|
Failure of long-term lamivudine prophylaxis in patients with resolved hepatitis B infection undergoing chemotherapy and allogenic hematopoietic stem cell transplantation for hematological malignancies: two case reports.
Topics: Antiviral Agents; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lamivudine; Male; Middle Aged; Premedication; Treatment Failure; Virus Activation | 2017 |
Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Female; Hematologic Neoplasms; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunosuppressive Agents; Lamivudine; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Male; Middle Aged; Virus Activation; Young Adult | 2018 |
Efficacy of lamivudine prophylaxis in preventing hepatitis B virus reactivation in patients with resolved infection undergoing allogeneic SCT and receiving rituximab.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antiviral Agents; Female; Hematologic Neoplasms; Hepatitis B; Hepatitis B virus; Humans; Italy; Lamivudine; Male; Middle Aged; Rituximab; Stem Cell Transplantation; Virus Activation; Young Adult | 2019 |
Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor.
Topics: Adult; Carrier State; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Male; Middle Aged; Transplantation, Autologous; Transplantation, Homologous; Virus Activation | 2016 |
Lamivudine prophylaxis and hepatitis B vaccination for prevention of hepatitis B virus reverse seroconversion in long-term survivors after allogeneic stem cell transplantation.
Topics: Aged; Anti-HIV Agents; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hepatitis B; Hepatitis B Vaccines; Hepatitis B virus; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Risk Factors; Time Factors; Transplantation, Homologous; Vaccination; Virus Activation | 2009 |
Frequency of hepatitis B virus mutant in asymptomatic hepatitis B virus carriers receiving prophylactic lamivudine during chemotherapy for hematologic malignancies.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Carrier State; DNA, Viral; Female; Hematologic Neoplasms; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Male; Mutation | 2004 |
Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carrier State; Female; Hematologic Neoplasms; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Japan; Lamivudine; Liver; Male; Middle Aged; Prevalence; Reverse Transcriptase Inhibitors; Virus Activation | 2005 |
[Effect of lamivudine for hepatitis B virus reactivation in blood cancer patients undergoing immunosuppressive chemotherapy].
Topics: Adult; Aged; Antineoplastic Agents; Antiviral Agents; Bone Marrow Transplantation; Female; Hematologic Neoplasms; Hepatitis B; Hepatitis B virus; Humans; Immunocompromised Host; Immunosuppressive Agents; Lamivudine; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Virus Activation | 2004 |
Lamivudine prophylaxis in HBV carriers with haemato-oncological malignancies who receive chemotherapy.
Topics: Antiviral Agents; Carrier State; Hematologic Neoplasms; Hepatitis B; Humans; Lamivudine; Time Factors; Virus Activation | 2005 |
Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antiviral Agents; DNA, Viral; Female; Follow-Up Studies; Hematologic Neoplasms; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Immunocompromised Host; Lamivudine; Male; Middle Aged; Virus Activation | 2005 |
Duration of lamivudine prophylaxis in inactive hepatitis B virus carriers with haemato/oncological malignancies who receive chemotherapy.
Topics: Antineoplastic Agents; Antiviral Agents; Drug Administration Schedule; Hematologic Neoplasms; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Virus Activation | 2006 |
Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hodgkin Disease; Humans; Lamivudine; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Pilot Projects; Prednisone; Vidarabine; Vincristine; Virus Activation | 2001 |
Efficacy of Lamivudine in patients with hematologic malignancies receiving chemotherapy and precore mutant chronic active hepatitis B.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; DNA, Viral; False Negative Reactions; Female; Hematologic Neoplasms; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors; Therapeutic Equivalency | 2002 |